Donor HSCs with a preexisting ASXL1-mutation evoluting FLT3-ITD positive AML-M2 and FLT3-ITD negative AML-M5 in the donor and recipient respectively: one case analysis and literatures review.
10.3760/cma.j.issn.0253-2727.2019.04.012
- VernacularTitle:携带ASXL1突变干细胞在供受者体内分别发展为FLT3-ITD阳性AML-M2及FLT3-ITD阴性AML-M5一例报告并文献复习
- Author:
Dai KONG
1
;
Kai SUN
1
;
Ming Yue SHI
1
;
Yong Ping SONG
2
;
Mei Ying WEN
3
;
Zhong Wen LIU
1
Author Information
1. Department of Hematology, Henan Province People's Hospital and Zhengzhou University People's Hospital, Zhengzhou 450003, China.
2. Henan Tumor Hospital Affiliated to Zhengzhou University, Zhengzhou 450008, China.
3. Henan Provincial Center for China Marrow Donor Program, Zhengzhou 450003, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Leukemia, Myeloid, Acute;
Mutation;
Repressor Proteins;
Tissue Donors;
fms-Like Tyrosine Kinase 3
- From:
Chinese Journal of Hematology
2019;40(4):327-329
- CountryChina
- Language:Chinese
